Long-Term Follow-Up of Patients Who Received Gene-Modified Cell Therapy

NCT05472649 · tracked via the Priya Life Science USA tracker

Sponsor

Sorrento Therapeutics, Inc.

Phase

Observational

Started

2021-06-16

Last updated

2023-01-23

Condition(s) studied

Long-term Follow-up

Investigational drug(s) / intervention(s)

Gene-Modified Cell Therapy

Gene-Modified Cell Therapy: No investigational cell product will be administered

Study summary

Observational long-term follow-up study of patients who have been exposed to a gene-modified cell therapy produced by ex vivo transduction of immune cells expressing viral or non-viral vectors in studies sponsored by Sorrento Therapeutics, Inc.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * Patients must have received any amount of a CGT in a study sponsored by Sorrento Therapeutics, Inc. Exclusion Criteria: * Unable or unwilling to provide written informed consent and/or comply with study requirements.

Primary outcome measure(s)

Long-term safety of previous treatment with gene-modified cells — Baseline through end of study (approximately 15 years)
Long-term safety of previous treatment as assessed by incidence of adverse events (AEs)

Trial sites (1)

Facility	City	Region	Status
Abramson Cancer Center Clinical Research Unit, University of Pennsylvania	Philadelphia	Pennsylvania

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05472649 on ClinicalTrials.gov ↗ ← All trials in the USA